An ROR1 bi-specific T-cell engager provides effective targeting and cytotoxicity against a range of solid tumors

A ROR1–HER3–lncRNA signalling axis modulates the Hippo–YAP pathway to regulate bone metastasis

(2017) Chunlai Li et al.   NATURE CELL BIOLOGY

Distinct Patterns of Stromal and Tumor Expression of ROR1 and ROR2 in Histological Subtypes of Epithelial Ovarian Cancer

(2017) C.E. Henry et al.   Translational Oncology

Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma

(2016) A. Viardot et al.   BLOOD

High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia

(2016) B. Cui et al.   BLOOD

Chimeric antigen receptor T cell therapy: 25years in the making

(2016) Saar Gill et al.   BLOOD REVIEWS

Targeting ROR1 inhibits the self-renewal and invasive ability of glioblastoma stem cells

(2016) Eun-Hwa Jung et al.   CELL BIOCHEMISTRY AND FUNCTION

Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study

(2016) Maria-Elisabeth Goebeler et al.   JOURNAL OF CLINICAL ONCOLOGY

A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo

(2016) S Hipp et al.   LEUKEMIA

Expression of ROR1 has prognostic significance in triple negative breast cancer

(2016) Hui-Ping Chien et al.   VIRCHOWS ARCHIV

ROR1 is a novel prognostic biomarker in patients with lung adenocarcinoma

(2016) Yu-Zhu Zheng et al.   Scientific Reports

Expression of ROR1, pAkt, and pCREB in gastric adenocarcinoma

(2015) Hyeyoon Chang et al.   Annals of Diagnostic Pathology

Pre-clinical Specificity and Safety of UC-961, a First-In-Class Monoclonal Antibody Targeting ROR1

(2015) Michael Y. Choi et al.   Clinical Lymphoma Myeloma & Leukemia

ROR1-targeted delivery of OSU-2S, a nonimmunosuppressive FTY720 derivative, exerts potent cytotoxicity in mantle-cell lymphoma in vitro and in vivo

(2015) Rajeswaran Mani et al.   EXPERIMENTAL HEMATOLOGY

miR-382 inhibits migration and invasion by targeting ROR1 through regulating EMT in ovarian cancer

(2015) HONG TAN et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

ROR1 contributes to melanoma cell growth and migration by regulating N-cadherin expression via the PI3K/Akt pathway

(2015) Natalia Brenda Fernández et al.   MOLECULAR CARCINOGENESIS

Receptor tyrosine kinase gene expression profiles of Ewing sarcomas reveal ROR1 as a potential therapeutic target in metastatic disease

(2015) Jenny Potratz et al.   Molecular Oncology

Anti-CD20/CD3 T cell–dependent bispecific antibody for the treatment of B cell malignancies

(2015) Liping L. Sun et al.   Science Translational Medicine

Targeting the ROR1 and ROR2 receptors in epithelial ovarian cancer inhibits cell migration and invasion

(2015) Claire Henry et al.   Oncotarget

Are BiTEs the “missing link” in cancer therapy?

(2015) Carter M Suryadevara et al.   OncoImmunology

Silencing of Receptor Tyrosine Kinase ROR1 Inhibits Tumor-Cell Proliferation via PI3K/AKT/mTOR Signaling Pathway in Lung Adenocarcinoma

(2015) Yanchun Liu et al.   PLoS One

Solitomab, an epithelial cell adhesion molecule/CD3 bispecific antibody (BiTE), is highly active against primary chemotherapy-resistant ovarian cancer cell lines in vitro and fresh tumor cells ex vivo

(2014) Diana P. English et al.   CANCER

Bispecific T-cell engagers for cancer immunotherapy

(2014) Amelia M Huehls et al.   IMMUNOLOGY AND CELL BIOLOGY

CEA/CD3 bispecific antibody MEDI-565/AMG 211 activation of T cells and subsequent killing of human tumors is independent of mutations commonly found in colorectal adenocarcinomas

(2014) Michael D Oberst et al.   mAbs

Ovarian cancer stem cells express ROR1, which can be targeted for anti–cancer-stem-cell therapy

(2014) Suping Zhang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

ROR1 expression correlated with poor clinical outcome in human ovarian cancer

(2014) Huilin Zhang et al.   Scientific Reports

Safety of Targeting ROR1 in Primates with Chimeric Antigen Receptor-Modified T Cells

(2014) C. Berger et al.   Cancer Immunology Research

Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia

(2013) Stephan A. Grupp et al.   NEW ENGLAND JOURNAL OF MEDICINE

Hypoxia Induces Phenotypic Plasticity and Therapy Resistance in Melanoma via the Tyrosine Kinase Receptors ROR1 and ROR2

(2013) M. P. O'Connell et al.   Cancer Discovery

The Onco-Embryonic Antigen ROR1 Is Expressed by a Variety of Human Cancers

(2012) Suping Zhang et al.   AMERICAN JOURNAL OF PATHOLOGY

Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL

(2012) M. S. Topp et al.   BLOOD

Crosstalk between ROR1 and the Pre-B Cell Receptor Promotes Survival of t(1;19) Acute Lymphoblastic Leukemia

(2012) Vincent T. Bicocca et al.   CANCER CELL

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Blinatumomab: A historical perspective

(2012) Dirk Nagorsen et al.   PHARMACOLOGY & THERAPEUTICS

ROR1 Is Expressed in Human Breast Cancer and Associated with Enhanced Tumor-Cell Growth

(2012) Suping Zhang et al.   PLoS One

Restricted Cell Surface Expression of Receptor Tyrosine Kinase ROR1 in Pediatric B-Lineage Acute Lymphoblastic Leukemia Suggests Targetability with Therapeutic Monoclonal Antibodies

(2012) Hema Dave et al.   PLoS One

Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia

(2011) David L. Porter et al.   NEW ENGLAND JOURNAL OF MEDICINE

ROR1 expression is not a unique marker of CLL

(2010) Gábor Barna et al.   HEMATOLOGICAL ONCOLOGY

Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma

(2010) Richard E. Royal et al.   JOURNAL OF IMMUNOTHERAPY

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

(2010) M Hallek et al.   LANCET

Unique Cell Surface Expression of Receptor Tyrosine Kinase ROR1 in Human B-Cell Chronic Lymphocytic Leukemia

(2008) S. Baskar et al.   CLINICAL CANCER RESEARCH

Ror1, a cell surface receptor tyrosine kinase is expressed in chronic lymphocytic leukemia and may serve as a putative target for therapy

(2008) Amir H. DaneshManesh et al.   INTERNATIONAL JOURNAL OF CANCER

IMGT/V-QUEST: the highly customized and integrated system for IG and TR standardized V-J and V-D-J sequence analysis

(2008) X. Brochet et al.   NUCLEIC ACIDS RESEARCH

Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a

(2008) T. Fukuda et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Tumor Regression in Cancer Patients by Very Low Doses of a T Cell-Engaging Antibody

(2008) R. Bargou et al.   SCIENCE